Great question. We haven't tested the entire FDA pharmacopeia but we've looked at a lot of psychoactive drugs, and a dozen or so non-psychoactives. Short answer is membrane accumulation is a general property of cationic amphipaths, but there appears to be specificity of accumulation.

For example, we've done EM studies on yeast cells treated with amiodarone, an antiarrhythmic agent. We see evidence of membrane accumulation, but the ultrastructural features are not identical to those of sertraline-treated yeast cells, though there is overlap.

In work that is being written up now, we've looked for specificity determinants of membrane accumulation by a diverse set of psychoactive drugs, including multiple generations of antidepressants, antipsychotics and antihistamines. Yeast cells can actually tell the difference between closely related drugs, e.g., secondary amine tricyclics vs tertiary amine tricyclics. I think there's this notion that drug-membrane interactions are necessarily non-specific, but I don't believe this to be the case.

As for connecting membrane accumulation back to antidepressant effects on the brain, we proposed a simple model in the discussion of this paper. We are in the process of finding collaborators who would be interested in testing our ideas. If you know any good mouse psychiatrists, please forward my contact info! ;)